For treating the initial stages of MASLD, we believe that addressing the metabolic risk factors related to triglyceride-adiponectin balance, and glucose and lipid metabolism should be kept in mind, whereas liver-specific drug targets to reverse inflammation and collagen deposition become more crucial when the disease progresses to advanced fibrosis and cirrhosis. The gene discussed is ADIPOQ; the disease is Cirrhosis.